IMR Press / FBL / Volume 23 / Issue 11 / DOI: 10.2741/4696

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

PET/CT in the diagnosis and prognosis of osteosarcoma

Show Less
1 Department of radiology, Shanxi Cancer hospital and institute, Taiyuan, Shanxi, 030013, China
2 Department of bone and tissue tumor, Shanxi Cancer hospital and institute, Taiyuan, Shanxi, 030013, China
Front. Biosci. (Landmark Ed) 2018, 23(11), 2157–2165; https://doi.org/10.2741/4696
Published: 1 June 2018
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

Osteosarcoma is an aggressive malignancy that usually occurs in children and young adults, and long-term survival is only about 20% in patients with metastasis or recurrent disease. Traditional non-invasive techniques, such as positron-emission tomography (PET) scanning, magnetic resonance imaging (MRI) or computed tomography (CT) scanning, may not identify single lesions in the early stage or accurately detect small lesions. A novel technique, positron emission tomography/computed tomography (PET/CT), which is widely used in clinical practice, shows more accuracy, sensitivity, and specificity in the diagnosis of osteosarcoma. PET/CT provides information not only for diagnosis of primary lesion and metastases, but also for histological response to neoadjuvant chemotherapy and prognosis. Here, we review the role of PET/CT in the diagnosis and prognosis of osteosarcoma.

Keywords
Malignancy
Osteosarcoma
PET
CT
Review
Share
Back to top